GLP-1 Drugs: A Breakthrough in Diabetes and Obesity Management with Emerging Regulatory Challenges

Understanding the Diabetes–Obesity Link

There exists a strong and well-established relationship between obesity and Type 2 diabetes. Obesity, particularly central or abdominal obesity, increases insulin resistance, thereby making it difficult for the body to regulate blood sugar levels. In India, obesity is defined at a lower Body Mass Index (BMI ≥ 25 kg/m²) compared to global standards due to higher metabolic risks among Asian populations.
Type 2 diabetes is largely preventable and is associated with lifestyle factors such as sedentary behavior, unhealthy diet, excess sugar consumption, and genetic predisposition. At the same time, obesity is also a chronic and preventable condition that contributes significantly to non-communicable diseases (NCDs), including cardiovascular diseases and certain cancers.

What are GLP-1 Drugs?

GLP-1 (Glucagon-Like Peptide-1) receptor agonists are a class of medications designed to mimic the action of the natural GLP-1 hormone in the body. This hormone is released in response to food intake and plays a crucial role in maintaining glucose homeostasis.

These drugs work through multiple mechanisms:
1. They stimulate insulin secretion from the pancreas in a glucose-dependent manner.
2. They suppress the release of glucagon, thereby preventing excess glucose production by the liver.
3. They slow down gastric emptying, leading to prolonged digestion.
4. They increase satiety, thereby reducing appetite and promoting weight loss.
Due to these combined effects, GLP-1 drugs are effective not only in controlling blood sugar levels but also in managing obesity, making them a dual-benefit therapeutic option.

Types of GLP-1 Drugs Available

Several GLP-1 receptor agonists are currently available in the market, including:
1. Semaglutide (available in both injectable and oral forms)
2. Liraglutide
3. Tirzepatide (dual GIP and GLP-1 agonist)
4. Dulaglutide
5. Exenatide (including extended-release formulations)

Therapeutic Benefits

1. Effective Glycaemic Control: They help maintain stable blood sugar levels without causing significant hypoglycaemia.
2. Weight Loss: By suppressing appetite and delaying gastric emptying, these drugs promote sustained weight loss.
3. Cardiovascular Benefits: Some GLP-1 drugs have shown protective effects against cardiovascular diseases.
4. Improved Patient Compliance: Weekly dosing options improve adherence compared to daily medications.

Emerging Concerns in India

1. Off-label Use: Many individuals are using these drugs purely for cosmetic weight loss rather than medical necessity.
2. Unregulated Availability: These drugs are being sold through online pharmacies, wellness clinics, and even retail outlets without proper prescriptions.
3. Misleading Advertisements: Aggressive marketing campaigns are promoting these drugs as “miracle weight-loss solutions.”
4. Health Inequality: These drugs are expensive, making them accessible only to affluent sections of society.
5. Potential Misuse: Self-medication can lead to serious health complications.

Global Perspective

Globally, GLP-1 drugs have gained significant traction since their first approval by the U.S. Food and Drug Administration (FDA) in 2005. Countries across the world are witnessing a surge in demand, particularly for drugs like semaglutide, which are widely used for weight loss. However, the global experience also highlights similar challenges, including overuse, ethical concerns in marketing, and the need for robust regulatory mechanisms.

Way Forward

1. Strengthening Regulation: Strict monitoring of supply chains and online platforms.
2. Awareness Campaigns: Educating the public about the risks of unsupervised drug use.
3. Promoting Lifestyle Changes: Encouraging diet modification and physical activity as primary interventions.
4. Ethical Marketing Practices: Ensuring pharmaceutical companies adhere to responsible advertising norms.
5. Integration with Public Health Programs: Linking drug therapy with national NCD control programs.
6. Affordable Access: Exploring ways to make these drugs accessible to a wider population.